News Releases

Protox Therapeutics to Present at Technology and Life Sciences Forum

Wednesday, June 7, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox‘s President and Chief Executive Officer, will be a featured presenter at the 2006 Fasken Martineau Technology and Life Sciences Forum to be held June 13, 2006 at the Hyatt Regency Vancouver in British Columbia.

The 2006 Fasken Martineau Technology and Life Sciences Forum is a full day event in which public companies from British Columbia's technology and life sciences industries present their technology and progress to members of the investment community.

Dr. Merchant‘s presentation will take place at 10:00a.m. PST in the Regency A Room. For more information about the forum, visit the forum website at www.faskenforum.com or contact Jennifer Despins at Fasken Martineau directly at 604-631-3296 or faskenforum@van.fasken.com.

About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company’s PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, pro-aerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox is in Phase I clinical trial with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.

For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com